Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
- PMID: 29644539
- PMCID: PMC5960490
- DOI: 10.1007/s12325-018-0693-1
Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
Abstract
Introduction: Recent developments in the care of patients with idiopathic pulmonary fibrosis have the potential to improve survival rates. Population-based estimates of the current disease burden are needed to evaluate the future impact of newly approved therapies. The objective of this study is to describe incidence, prevalence, and survival of idiopathic pulmonary fibrosis patients in the UK.
Methods: Between 2000 and 2012, a patient cohort (N = 9,748,108), identified from Clinical Practice Research Datalink primary care data, was used to identify incident and prevalent cases of idiopathic pulmonary fibrosis-clinical syndrome. Incident cases were followed up to identify deaths. Poisson and Cox regressions were used to calculate incidence rate ratios (IRR) and hazard ratios for mortality, respectively. Adjustments were made for age, gender, and strategic health authority. Survival from diagnosis was estimated using Kaplan-Meier analysis.
Results: In total 1491 and 4527 incident cases were identified using narrow and broad idiopathic pulmonary fibrosis-clinical syndrome definitions, respectively. Incidence and prevalence increased during the study. Compared with 2000, a near 80% increase in incidence was observed by 2012 [IRR 1.78 (95% CI 1.50-2.11; broad definition)], despite an observed decrease using the narrow definition [0.50 (0.38-0.65)]. Median survival was 3.0 years (95% CI 2.8-3.1) and 2.7 years (95% CI 2.5-3.0) in broad (n = 2168) and narrow case sets (n = 996), respectively. No significant changes in survival were observed.
Conclusions: Idiopathic pulmonary fibrosis incidence rates have increased since 2000 and survival remains poor. These results provide a benchmark against which the effects of future treatment changes can be measured.
Funding: InterMune UK and Ireland (now part of F. Hoffman La Roche).
Keywords: CPRD GOLD; Idiopathic pulmonary fibrosis; Incidence; Population-based study; Prevalence; Respiratory; Survival.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5960490/bin/12325_2018_693_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5960490/bin/12325_2018_693_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5960490/bin/12325_2018_693_Fig3_HTML.gif)
![Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5960490/bin/12325_2018_693_Fig4_HTML.gif)
Similar articles
-
Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.Lancet Respir Med. 2014 Jul;2(7):566-72. doi: 10.1016/S2213-2600(14)70101-8. Epub 2014 May 27. Lancet Respir Med. 2014. PMID: 24875841
-
Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in England from 2008 to 2018: a cohort study.Thorax. 2024 Jun 14;79(7):624-631. doi: 10.1136/thorax-2023-220887. Thorax. 2024. PMID: 38688708
-
Delineating excess comorbidities in idiopathic pulmonary fibrosis: an observational study.Respir Res. 2024 Jun 19;25(1):249. doi: 10.1186/s12931-024-02875-2. Respir Res. 2024. PMID: 38898447 Free PMC article.
-
Idiopathic pulmonary fibrosis: diagnosis and epidemiology.Clin Chest Med. 2012 Mar;33(1):41-50. doi: 10.1016/j.ccm.2011.12.001. Clin Chest Med. 2012. PMID: 22365244 Review.
-
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.Eur Respir Rev. 2012 Dec 1;21(126):355-61. doi: 10.1183/09059180.00002512. Eur Respir Rev. 2012. PMID: 23204124 Free PMC article. Review.
Cited by
-
Potential role of SIRT-1 and SIRT-3 as biomarkers for the diagnosis and prognosis of idiopathic pulmonary fibrosis.Respir Res. 2024 Apr 27;25(1):189. doi: 10.1186/s12931-024-02796-0. Respir Res. 2024. PMID: 38678247 Free PMC article.
-
A Harmonised Approach to Curating Research-Ready Datasets for Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Interstitial Lung Disease (ILD) in England, Wales and Scotland Using Clinical Practice Research Datalink (CPRD), Secure Anonymised Information Linkage (SAIL) Databank and DataLoch.Clin Epidemiol. 2024 Apr 4;16:235-247. doi: 10.2147/CLEP.S437937. eCollection 2024. Clin Epidemiol. 2024. PMID: 38595770 Free PMC article.
-
MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution.J Clin Invest. 2024 Mar 21;134(10):e172826. doi: 10.1172/JCI172826. J Clin Invest. 2024. PMID: 38512415 Free PMC article.
-
REMOTE-ILD study: Description of the protocol for a multicentre, 12-month randomised controlled trial to assess the clinical and cost-effectiveness of remote monitoring of spirometry and pulse oximetry in patients with interstitial lung disease.BMJ Open Respir Res. 2024 Feb 28;11(1):e002067. doi: 10.1136/bmjresp-2023-002067. BMJ Open Respir Res. 2024. PMID: 38418384 Free PMC article.
-
A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials.BMC Pulm Med. 2024 Jan 27;24(1):58. doi: 10.1186/s12890-024-02861-w. BMC Pulm Med. 2024. PMID: 38281037 Free PMC article.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical